ES2006941A6 - Vaccines and immunoassays for acquired immune deficiency syndrome - Google Patents
Vaccines and immunoassays for acquired immune deficiency syndromeInfo
- Publication number
- ES2006941A6 ES2006941A6 ES8801494A ES8801494A ES2006941A6 ES 2006941 A6 ES2006941 A6 ES 2006941A6 ES 8801494 A ES8801494 A ES 8801494A ES 8801494 A ES8801494 A ES 8801494A ES 2006941 A6 ES2006941 A6 ES 2006941A6
- Authority
- ES
- Spain
- Prior art keywords
- immunoassays
- vaccines
- immune deficiency
- protein
- deficiency syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 208000030507 AIDS Diseases 0.000 title abstract 2
- 238000003018 immunoassay Methods 0.000 title abstract 2
- 208000011580 syndromic disease Diseases 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 2
- 210000004748 cultured cell Anatomy 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000008771 Lymphadenopathy Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 208000018555 lymphatic system disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001175 peptic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
A method of producing a peptide or protein related to an epitope associated virus lymphadenopathy / leukemia virus human t cells (lav / htlv-iii), in which is purified the peptide or protein from a cultured cell containing a sequence of nucleotides encoding peptic or protein of lav / htlv-iii under control of a second nucleotide sequence that regulates the expression of the gene so that the epitope expressed by the cultured cell. The invention is especially useful in connection with immunoassays for vaccines and acquired immune deficiency syndrome (aids). (Machine-translation by Google Translate, not legally binding)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77990985A | 1985-09-25 | 1985-09-25 | |
US84298486A | 1986-03-27 | 1986-03-27 | |
US90521786A | 1986-09-09 | 1986-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2006941A6 true ES2006941A6 (en) | 1989-05-16 |
Family
ID=27419757
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES8602123A Expired ES2002490A6 (en) | 1985-09-25 | 1986-09-24 | Vaccines and immunoassays for acquired immune deficiency syndrome |
ES8801494A Expired ES2006941A6 (en) | 1985-09-25 | 1988-05-13 | Vaccines and immunoassays for acquired immune deficiency syndrome |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES8602123A Expired ES2002490A6 (en) | 1985-09-25 | 1986-09-24 | Vaccines and immunoassays for acquired immune deficiency syndrome |
Country Status (22)
Country | Link |
---|---|
CN (1) | CN1020752C (en) |
AT (1) | ATA256786A (en) |
CH (1) | CH676247A5 (en) |
DE (1) | DE3690508T1 (en) |
DK (1) | DK455486A (en) |
ES (2) | ES2002490A6 (en) |
FI (1) | FI863848A (en) |
FR (1) | FR2587720A2 (en) |
GB (1) | GB2181435B (en) |
GR (1) | GR862412B (en) |
HU (1) | HU205780B (en) |
IE (1) | IE59314B1 (en) |
IL (1) | IL80073A (en) |
IT (1) | IT1195829B (en) |
MY (1) | MY103182A (en) |
NL (1) | NL8602422A (en) |
NO (1) | NO863803L (en) |
NZ (1) | NZ217645A (en) |
PT (1) | PT83434B (en) |
SE (4) | SE8604007L (en) |
WO (1) | WO1987002038A1 (en) |
YU (1) | YU46753B (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3650011T2 (en) * | 1985-04-08 | 1994-11-17 | Genetic Systems Corp | EXPRESSION AND DIAGNOSIS WITH GAG-CODED PEPTIDES THAT ARE IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES AGAINST LAV. |
US4734362A (en) * | 1986-02-03 | 1988-03-29 | Cambridge Bioscience Corporation | Process for purifying recombinant proteins, and products thereof |
US4925784A (en) * | 1986-04-04 | 1990-05-15 | Hoffmann-La Roche Inc. | Expression and purification of an HTLV-III gag/env gene protein |
US4983387A (en) * | 1986-05-19 | 1991-01-08 | Viral Technologies Inc. | HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus |
ATE107861T1 (en) * | 1986-09-19 | 1994-07-15 | Oncogen | USE OF ACTIVATED T-LYMPHOCYTES TO PREPARE A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AIDS. |
IL84154A0 (en) * | 1986-10-16 | 1988-03-31 | Microgenesys Inc | Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same |
JPS63258575A (en) * | 1986-12-15 | 1988-10-26 | レプリゲン コーポレーション | Recombinant hiv envelope protein produced in insect cell |
ES2104556T3 (en) * | 1987-01-16 | 1997-10-16 | Pasteur Institut | PEPTIDES THAT HAVE IMMUNOLOGICAL PROPERTIES OF HIV-2. |
FR2610632B1 (en) * | 1987-02-11 | 1990-12-21 | Pasteur Institut | CHARACTERISTIC PEPTIDES OF HUMAN IMMUNODEFICIENCY RETROVIRUSES (HIV VIRUSES) THEIR APPLICATIONS IN THE DIAGNOSIS OF INFECTIONS DUE TO CERTAIN OF THESE VIRUSES AND, IF NECESSARY, IN VACCINATION AGAINST AIDS |
US5681713A (en) * | 1987-05-08 | 1997-10-28 | Smithkline Beecham Corporation | Expression of heterologous proteins in Drosophila cells |
GB8714802D0 (en) * | 1987-06-24 | 1987-07-29 | Proteus Biotech Ltd | Synthetic polypeptides |
DE10399031I1 (en) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Recombinant viruses. |
FR2620030B1 (en) * | 1987-09-07 | 1990-03-23 | Transgene Sa | VECTOR FOR THE EXPRESSION OF PROTEINS OF HIV-2 VIRUS, A CAUSAL AGENT FOR AIDS, CELL CULTURE INFECTED OR TRANSFORMED THROUGH THIS VECTOR, PROTEINS OBTAINED, VACCINE AND ANTIBODIES OBTAINED |
IL89118A0 (en) * | 1988-02-03 | 1989-08-15 | Microgenesys Inc | Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1 |
US5763160A (en) * | 1988-02-12 | 1998-06-09 | United Biomedical, Inc. | Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines |
EP0343132B1 (en) * | 1988-05-06 | 1994-08-17 | Ferropas Ag | Methods and systems for producing HIV antigens |
US5043262A (en) * | 1988-05-12 | 1991-08-27 | Dana Farber Cancer Institute | Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use |
AP129A (en) * | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
US5614404A (en) * | 1988-06-10 | 1997-03-25 | Theriod Biologics, Incorporated | Self-assembled, defective, non-self-propagating lentivirus particles |
WO1989012095A1 (en) * | 1988-06-10 | 1989-12-14 | Applied Biotechnology, Inc. | A method of evaluating recombinant vaccines against immunodeficiency virus |
US5631154A (en) * | 1988-06-10 | 1997-05-20 | Therion Biologics, Incorporated | Self assembled, defective, non-self-propagating lentivirus particles |
US5747324A (en) * | 1988-06-10 | 1998-05-05 | Therion Biologics Corporation | Self-assembled, defective, non-self-propagating lentivirus particles |
US5665577A (en) * | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
ATE160377T1 (en) * | 1989-04-18 | 1997-12-15 | Applied Biotechnology Inc | GENERATION OF HYBRID GENES AND PROTEINS BY RECOMBINATION USING VIRUSES |
ATE235554T1 (en) * | 1989-06-01 | 2003-04-15 | Applied Biotechnology Inc | RECOMBINANT VECTORS THAT CODE FOR SELF-ASSEMBLY, DEFECTIVE, NON-SELF-PROPIFYING VIRUS PARTICLES |
GB8923123D0 (en) | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
US5981276A (en) * | 1990-06-20 | 1999-11-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
US5840312A (en) * | 1991-05-02 | 1998-11-24 | Institut Pasteur | Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein |
FR2676068B1 (en) * | 1991-05-02 | 1994-11-04 | Pasteur Institut | IMMUNOGENIC RECOMBINANT STRAINS OF B. ANTHRACIS - IMMUNOGENIC COMPOSITIONS CONTAINING THEM. |
KR100265393B1 (en) * | 1991-11-08 | 2000-10-02 | 로렌스 티. 마이젠헬더 | Feline leukemia virus vaccines |
DE4405810A1 (en) | 1994-02-23 | 1995-08-24 | Behringwerke Ag | Peptides derived from a retrovirus from the HIV group and their use |
JPH11511112A (en) | 1995-02-10 | 1999-09-28 | ユニバーシティ・オブ・マサチューセッツ | Delivery of exogenous compounds |
US6013506A (en) * | 1995-06-05 | 2000-01-11 | Wardley; Richard C. | Feline leukemia virus vaccines |
EP0762212B1 (en) * | 1995-09-06 | 2000-01-12 | Schablonentechnik Kufstein Aktiengesellschaft | Process for making a printing screen |
US5741492A (en) * | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
US6723558B1 (en) | 1996-01-23 | 2004-04-20 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
JP2005514393A (en) | 2001-12-19 | 2005-05-19 | ネクター セラピューティクス | Supplying aminoglycosides to the lung |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0127839B1 (en) * | 1983-05-27 | 1992-07-15 | THE TEXAS A&M UNIVERSITY SYSTEM | Method for producing a recombinant baculovirus expression vector |
US4662514A (en) * | 1983-11-01 | 1987-05-05 | Charleswater Products, Inc. | Electrically conductive polymeric tubes for static sensitive electronic devices |
IL76082A (en) * | 1984-08-22 | 1991-07-18 | Us Health | Molecular clones of the genome of htlv-iii and a process for the preparation thereof |
US9328391B1 (en) * | 1984-08-22 | 2016-05-03 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cloning and expression of HIV-1 DNA |
GB8501473D0 (en) * | 1985-01-21 | 1985-02-20 | Pasteur Institut | Cloned dna sequences |
IE64006B1 (en) * | 1984-10-18 | 1995-06-28 | Pasteur Institut | Antigens particulary envelope antigens of the virus of lymphadenopathies and of the acquired immune-deficiency syndrome and virus process for producing virus envelope antigens use of said antigens in the preparation of immunogenic compositions or for the diagnosis of the presence of antibodies against this virus |
CA1341482C (en) * | 1984-10-31 | 2005-05-10 | Paul A. Luciw | Process for preparing fragments of aids-associated retroviruses |
DE3588134T2 (en) * | 1984-12-24 | 1997-03-20 | Genentech Inc | Fusion of AIDS-related polypeptides |
US4774175A (en) * | 1985-03-01 | 1988-09-27 | Centocor, Inc. | Immunochemical methods for the detection of antibody against HTLV-III |
NZ215867A (en) * | 1985-04-19 | 1989-10-27 | Hoffmann La Roche | Aids envelope protein, dna vectors and method of production |
FR2586427B1 (en) * | 1985-08-20 | 1988-12-09 | Pasteur Institut | NUCLEOTIDE AND POLYPEPTIDE SEQUENCES FROM VISNA VIRUS AND THEIR APPLICATION TO DIAGNOSTIC TESTS AND THE PRODUCTION OF IMMUNOGENIC COMPOSITIONS |
-
1986
- 1986-09-22 NZ NZ217645A patent/NZ217645A/en unknown
- 1986-09-22 GR GR862412A patent/GR862412B/en unknown
- 1986-09-23 SE SE8604007A patent/SE8604007L/en not_active Application Discontinuation
- 1986-09-23 IE IE252586A patent/IE59314B1/en not_active IP Right Cessation
- 1986-09-24 DK DK455486A patent/DK455486A/en not_active Application Discontinuation
- 1986-09-24 GB GB8622987A patent/GB2181435B/en not_active Expired - Fee Related
- 1986-09-24 HU HU864072A patent/HU205780B/en not_active IP Right Cessation
- 1986-09-24 ES ES8602123A patent/ES2002490A6/en not_active Expired
- 1986-09-24 IT IT67730/86A patent/IT1195829B/en active
- 1986-09-24 NO NO863803A patent/NO863803L/en unknown
- 1986-09-24 FI FI863848A patent/FI863848A/en not_active IP Right Cessation
- 1986-09-24 CH CH3821/86A patent/CH676247A5/fr not_active IP Right Cessation
- 1986-09-25 NL NL8602422A patent/NL8602422A/en not_active Application Discontinuation
- 1986-09-25 CN CN86106632A patent/CN1020752C/en not_active Expired - Fee Related
- 1986-09-25 DE DE19863690508 patent/DE3690508T1/de not_active Withdrawn
- 1986-09-25 YU YU165486A patent/YU46753B/en unknown
- 1986-09-25 AT AT0256786A patent/ATA256786A/en unknown
- 1986-09-25 WO PCT/US1986/002002 patent/WO1987002038A1/en active Application Filing
- 1986-09-25 PT PT83434A patent/PT83434B/en not_active IP Right Cessation
- 1986-09-25 FR FR8613414A patent/FR2587720A2/en active Granted
- 1986-12-31 IL IL8007386A patent/IL80073A/en not_active IP Right Cessation
-
1987
- 1987-09-29 MY MYPI87002188A patent/MY103182A/en unknown
-
1988
- 1988-05-13 ES ES8801494A patent/ES2006941A6/en not_active Expired
-
1991
- 1991-10-14 SE SE9102976A patent/SE9102976L/en not_active Application Discontinuation
- 1991-10-14 SE SE9102975A patent/SE9102975L/en not_active Application Discontinuation
- 1991-10-14 SE SE9102974A patent/SE9102974L/en not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2006941A6 (en) | Vaccines and immunoassays for acquired immune deficiency syndrome | |
UA32548C2 (en) | Isolated DNA sequence coding EPSPS ferment, Isolated DNA sequence coding protein, revealING EPSPS activity, recombinant bifilar DNA molecule, a method for producing genetically transformed plants | |
YU45871B (en) | POLYPEPTIDE WITH HUMAN IMMUNOINTERFERON (IFN-GAMMA) PROPERTIES | |
MY121185A (en) | Recombinant antibodies for human therapy. | |
DE10399037I2 (en) | Recombinant virus proteins accompanied by lymphadenopathic sydrome and / or "Acquired Immune Deficiency Syndrome" (AIDS). | |
EP0185444A3 (en) | Cloning and expression of htlv-iii dna | |
DE3382694T2 (en) | EXPRESSION, PROCESSING AND SEPARATION OF HETEROLOGICAL PROTEIN BY YEAST. | |
HUT46061A (en) | Dna sequences encoding hirudin-like protein and process for producing such proteins | |
IL83192A (en) | Method for the preparation of proteins with factor viii activity by microbial host cells;expression vectors,host cells,antibodies | |
NO2009022I1 (en) | Protein-D; See other document (latest) | |
CA2095852A1 (en) | Proteins with changed epitopes and methods for the production thereof | |
AU1986588A (en) | Growth hormone receptor | |
ES8103976A1 (en) | Interferon proteins and method of producing same. | |
ES8500996A1 (en) | Novel DNA and use thereof. | |
OA08413A (en) | Monoclonal antibodies against proteins encoded by the genomic RNA of lymphadenopathy-associated-virus (LAV) and hybridomas secreting said antibodies. | |
AU621830B2 (en) | Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease | |
ATE109829T1 (en) | INTERLEUKINE-7. | |
EP0361284A3 (en) | T cell growth factor | |
ES8503371A1 (en) | Hybrid cell lines that produce immunoglobin, their use and process for preparing them. | |
AU7939894A (en) | Recombinant pilc proteins, process for producing them and their use | |
EP0196223A3 (en) | Dedicated ribosomes and their use in producing protein in cell culture | |
ES8609465A1 (en) | Monoclonal antibodies to human gamma-interferon, hybrid cell lines producing such antibodies, use of the antibodies and process for preparing them. | |
ES8606886A1 (en) | Immune interferon and method for its purification. | |
IT8421612A0 (en) | CLONING VECTOR, PROCEDURE FOR ITS CONSTRUCTION AND PROCEDURE FOR CONCENTRATION AND PURIFICATION OF PRODUCED PROTEINS, FORMED BY THE CLONING VECTOR. | |
IE871932L (en) | Method for the preparation of proteins with factor viii¹activity by microbial host cells, expression vectors, host¹cells, antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD1A | Patent lapsed |
Effective date: 20000601 |